- Home
- VFC vs RARE Comparison
VFC vs RARE Comparison
Compare VFC & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VFC
- RARE
- Stock Information
- Founded
- VFC 1899
- RARE 2010
- Country
- VFC United States
- RARE United States
- Employees
- VFC N/A
- RARE N/A
- Industry
- VFC Apparel
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- VFC Consumer Discretionary
- RARE Health Care
- Exchange
- VFC Nasdaq
- RARE Nasdaq
- Market Cap
- VFC 4.1B
- RARE 3.5B
- IPO Year
- VFC N/A
- RARE 2014
- Fundamental
- Price
- VFC $12.26
- RARE $26.23
- Analyst Decision
- VFC Buy
- RARE Strong Buy
- Analyst Count
- VFC 18
- RARE 15
- Target Price
- VFC $16.28
- RARE $87.40
- AVG Volume (30 Days)
- VFC 7.0M
- RARE 2.6M
- Earning Date
- VFC 07-30-2025
- RARE 07-31-2025
- Dividend Yield
- VFC 2.93%
- RARE N/A
- EPS Growth
- VFC N/A
- RARE N/A
- EPS
- VFC N/A
- RARE N/A
- Revenue
- VFC $9,504,691,000.00
- RARE $590,689,000.00
- Revenue This Year
- VFC $0.92
- RARE $18.94
- Revenue Next Year
- VFC $3.39
- RARE $28.61
- P/E Ratio
- VFC N/A
- RARE N/A
- Revenue Growth
- VFC N/A
- RARE 33.46
- 52 Week Low
- VFC $9.41
- RARE $26.01
- 52 Week High
- VFC $29.02
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- VFC 49.60
- RARE 27.80
- Support Level
- VFC $11.54
- RARE $26.85
- Resistance Level
- VFC $12.39
- RARE $42.37
- Average True Range (ATR)
- VFC 0.49
- RARE 1.72
- MACD
- VFC 0.02
- RARE -1.21
- Stochastic Oscillator
- VFC 46.13
- RARE 2.80
About VFC V.F. Corporation
VF designs, produces, and distributes branded apparel, footwear, and accessories. Its apparel categories are active, outdoor, and work. Its portfolio of 11 brands includes Vans, The North Face, Timberland, Altra, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. Tracing its roots to 1899, the company has evolved through many brand acquisitions and dispositions.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.